Projects per year
Personal profile
Chinese Name
Biography
Prof. Yu received his undergraduate education at the Henan University of Traditional Chinese Medicine, and obtained his PhD degree in biochemistry from the Hong Kong University of Science and Technology. Before joining the Hong Kong Baptist University, Prof. Yu once worked at China Pharmaceutical University, Nagasaki University, Hong Kong University of Science and Technology, Xiamen University and University of Macau. Prof. Yu is known for his research in herbal pharmacology, and in processing of Chinese medicinal materials. He has published more than 200 peer-reviewed research papers.
Consun Pharmaceutical Group Limited and Laboratory JaneClare Limited in collaboration with Prof. Yu's team established "Consun Chinese Medicines Research Centre for Renal Diseases" and "JaneClare Transdermal TCM Therapy Laboratory", respectively, in Hong Kong Baptist University.
Prof. Yu serves as Editorial Board Member/Associate Editor/Executive Editor/ Consulting Editor for more than 30 journals, e.g. LiShizhen Medicine and Materia Medica Research, BMC Complementary Medicine and Therapies, Current Topics in Nutraceutical Research, Journal of Alternative, Complementary & Integrative Medicine, Pharmacological Research.
Research Interests
1) Pharmacology of Chinese medicines, focusing on the mechanisms of action of anticancer, anti-inflammation and melanogenesis-modulation herbs; 2) Unique processing of Chinese medicinal herbs, focusing on the mechanisms underlying processing of Chinese medicines, standardization of adjuvant materials for the processing of Chinese medicinal herbs, and quality control of decoction pieces.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
- 1 Similar Scholars
Network
-
-
Does dihydroartemisinin overcome vemurafenib resistance in melanoma by suppressing FLI1 expression?
1/01/23 → …
Project: Research project
-
Ginsenoside Rg3 and Artesunate Synergistically Overcome Sorafenib Resistance in Hepatocellular Carcinoma: Pharmacological Effects and Mechanisms of Action
1/12/22 → 30/11/25
Project: Research project
-
Does upregulating RNF125 expression with luteolin overcome vemurafenib resistance in melanoma?
1/01/22 → 31/12/24
Project: Research project
-
-
An essential Noc3p dimerization cycle mediates ORC double-hexamer formation in replication licensing
Amin, A., Wu, R., Khan, M. A., Cheung, M. H., Liang, Y., Liu, C., Zhu, G., Yu, Z. L. & Liang, C., Mar 2023, In: Life Science Alliance. 6, 3, 22 p., e202201594.Research output: Contribution to journal › Article › peer-review
Open Access -
Arabidopsis DXO1 activates RNMT1 to methylate the mRNA guanosine cap
Xiao, C., Li, K., Hua, J., He, Z., Zhang, F., Li, Q., Zhang, H., Yang, L., Pan, S., Cai, Z., Yu, Z., Wong, K. B. & Xia, Y., 13 Jan 2023, In: Nature Communications. 14, 12 p., 202.Research output: Contribution to journal › Article › peer-review
Open Access -
Inhibition of STAT3 signaling contributes to the anti-melanoma effects of chrysoeriol
Liu, Y. X., Chen, Y. J., Xu, B. W., Fu, X. Q., Ding, W. J., Li, S. M. A., Wang, X. Q., Wu, J. Y., Wu, Y., Dou, X., Liu, B. & Yu, Z. L., Jan 2023, In: Phytomedicine. 109, 11 p., 154572.Research output: Contribution to journal › Article › peer-review
-
具有抗大腸癌效果的藥物組合及其應用
YU, Z., FU, X. & LI, J., 4 Apr 2023, IPC No. A61-YZ-ISO3-CN01, 22 Sept 2021, Priority date 22 Sept 2021, Priority No. CN 202111106787.6Research output: Patent
-
基於網絡藥理學探討靈芝治療特應性皮炎的分子作用機制及有效成分
丁卓然, 吳瑩, 符秀瓊 & 禹志領, Jan 2023, In: 香港中醫雜誌. 18, 1, 7 p., 12.Translated title of the contribution :Study on the molecular mechanisms and bioactive compounds of Ganoderma lucidum in the treatment of atopic dermatitis based on network pharmacology Research output: Contribution to journal › Article › peer-review